Safety and Efficacy of Drug-Eluting Bead Transarterial Chemoembolization Combined with Lenvatinib and Anti-PD-1 Antibodies for Unresectable Hepatocellular Carcinoma: A Retrospective Analysis
Shao-Jie Wu,1,2,* Dan-Dan Ruan,1,* Qiu-Yan Wu,1,* Yi Tang,1,2 Jian-Hui Zhang,1 Sen-Lin Cai,1,2 Yan-Feng Zhou,1,2 Jie-Wei Luo,1,3 Zhu-Ting Fang1,2 1Fujian Provincial Hospital, Shengli Clinical Medical College of Fujian Medical University, Fuzhou, People’s Republic of China; 2D...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2023-06-01
|
| Series: | Journal of Hepatocellular Carcinoma |
| Subjects: | |
| Online Access: | https://www.dovepress.com/safety-and-efficacy-of-drug-eluting-bead-transarterial-chemoembolizati-peer-reviewed-fulltext-article-JHC |
| _version_ | 1797810003774537728 |
|---|---|
| author | Wu SJ Ruan DD Wu QY Tang Y Zhang JH Cai SL Zhou YF Luo JW Fang ZT |
| author_facet | Wu SJ Ruan DD Wu QY Tang Y Zhang JH Cai SL Zhou YF Luo JW Fang ZT |
| author_sort | Wu SJ |
| collection | DOAJ |
| description | Shao-Jie Wu,1,2,* Dan-Dan Ruan,1,* Qiu-Yan Wu,1,* Yi Tang,1,2 Jian-Hui Zhang,1 Sen-Lin Cai,1,2 Yan-Feng Zhou,1,2 Jie-Wei Luo,1,3 Zhu-Ting Fang1,2 1Fujian Provincial Hospital, Shengli Clinical Medical College of Fujian Medical University, Fuzhou, People’s Republic of China; 2Department of Interventional Radiology, Fujian Provincial Hospital, Fuzhou, People’s Republic of China; 3Department of Traditional Chinese Medicine, Fujian provincial hospital, Fuzhou, People’s Republic of China*These authors contributed equally to this workCorrespondence: Jie-Wei Luo; Zhu-Ting Fang, Email docluo0421@aliyun.com; 470389481@qq.comBackground: Drug-eluting bead transarterial chemoembolization (DEB-TACE) has good efficacy in the treatment of unresectable hepatocellular carcinoma (uHCC), with a relatively high objective response rate (ORR) compared to conventional transarterial chemoembolization (cTACE). This study aimed to evaluate the safety and medium-term clinical efficacy of DEB-TACE combined with lenvatinib (LEN) plus PD-1 inhibitors as a triple therapy for the treatment of uHCC.Methods: Data of patients with uHCC who received triple therapy of DEB-TACE combined with LEN plus PD-1 inhibitors from January 2019 to June 2021 were analyzed retrospectively. The study endpoints were ORR, progression-free survival (PFS), and treatment-related adverse events based on the modified Response Evaluation Criteria in Solid Tumors (mRECIST).Results: Thirty-five patients were included in this study, with a median follow-up period of 15 months. The median cycle of DEB-TACE was 1, while that of all forms of TACE procedures per patient was 2. The median administration time of LEN was 7 months, and the median number of PD-1 inhibitor treatment was 4 cycles. The ORR based on mRECIST was 82.9%, disease control rate was 91.4%, and the median time to response was 7 weeks. Among these, the ORR of Barcelona Clinic Liver Cancer (BCLC) stage A reached 100%, while that of BCLC stages B and C reached 84.6% and 78.9%, respectively. The median PFS was 9 months; the mOS was not reached. Fourteen patients (40%) successfully underwent downstaging conversion and surgical resection, 32 patients (91.4%) experienced treatment-related adverse events, and no grade 5-related adverse reactions occurred.Conclusion: DEB-TACE combined with LEN and PD-1 inhibitors has a high ORR and surgical conversion rate in the treatment of uHCC tumors, and the toxicity and side effects were tolerable.Keywords: unresectable hepatocellular carcinoma, transarterial chemoembolization, drug-eluting bead, lenvatinib, PD-1 inhibitor, combined therapy |
| first_indexed | 2024-03-13T07:01:31Z |
| format | Article |
| id | doaj.art-bc38f4667a4c4a99887b7c8056becf56 |
| institution | Directory Open Access Journal |
| issn | 2253-5969 |
| language | English |
| last_indexed | 2024-03-13T07:01:31Z |
| publishDate | 2023-06-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Journal of Hepatocellular Carcinoma |
| spelling | doaj.art-bc38f4667a4c4a99887b7c8056becf562023-06-06T19:22:44ZengDove Medical PressJournal of Hepatocellular Carcinoma2253-59692023-06-01Volume 1080782084175Safety and Efficacy of Drug-Eluting Bead Transarterial Chemoembolization Combined with Lenvatinib and Anti-PD-1 Antibodies for Unresectable Hepatocellular Carcinoma: A Retrospective AnalysisWu SJRuan DDWu QYTang YZhang JHCai SLZhou YFLuo JWFang ZTShao-Jie Wu,1,2,* Dan-Dan Ruan,1,* Qiu-Yan Wu,1,* Yi Tang,1,2 Jian-Hui Zhang,1 Sen-Lin Cai,1,2 Yan-Feng Zhou,1,2 Jie-Wei Luo,1,3 Zhu-Ting Fang1,2 1Fujian Provincial Hospital, Shengli Clinical Medical College of Fujian Medical University, Fuzhou, People’s Republic of China; 2Department of Interventional Radiology, Fujian Provincial Hospital, Fuzhou, People’s Republic of China; 3Department of Traditional Chinese Medicine, Fujian provincial hospital, Fuzhou, People’s Republic of China*These authors contributed equally to this workCorrespondence: Jie-Wei Luo; Zhu-Ting Fang, Email docluo0421@aliyun.com; 470389481@qq.comBackground: Drug-eluting bead transarterial chemoembolization (DEB-TACE) has good efficacy in the treatment of unresectable hepatocellular carcinoma (uHCC), with a relatively high objective response rate (ORR) compared to conventional transarterial chemoembolization (cTACE). This study aimed to evaluate the safety and medium-term clinical efficacy of DEB-TACE combined with lenvatinib (LEN) plus PD-1 inhibitors as a triple therapy for the treatment of uHCC.Methods: Data of patients with uHCC who received triple therapy of DEB-TACE combined with LEN plus PD-1 inhibitors from January 2019 to June 2021 were analyzed retrospectively. The study endpoints were ORR, progression-free survival (PFS), and treatment-related adverse events based on the modified Response Evaluation Criteria in Solid Tumors (mRECIST).Results: Thirty-five patients were included in this study, with a median follow-up period of 15 months. The median cycle of DEB-TACE was 1, while that of all forms of TACE procedures per patient was 2. The median administration time of LEN was 7 months, and the median number of PD-1 inhibitor treatment was 4 cycles. The ORR based on mRECIST was 82.9%, disease control rate was 91.4%, and the median time to response was 7 weeks. Among these, the ORR of Barcelona Clinic Liver Cancer (BCLC) stage A reached 100%, while that of BCLC stages B and C reached 84.6% and 78.9%, respectively. The median PFS was 9 months; the mOS was not reached. Fourteen patients (40%) successfully underwent downstaging conversion and surgical resection, 32 patients (91.4%) experienced treatment-related adverse events, and no grade 5-related adverse reactions occurred.Conclusion: DEB-TACE combined with LEN and PD-1 inhibitors has a high ORR and surgical conversion rate in the treatment of uHCC tumors, and the toxicity and side effects were tolerable.Keywords: unresectable hepatocellular carcinoma, transarterial chemoembolization, drug-eluting bead, lenvatinib, PD-1 inhibitor, combined therapyhttps://www.dovepress.com/safety-and-efficacy-of-drug-eluting-bead-transarterial-chemoembolizati-peer-reviewed-fulltext-article-JHCunresectable hepatocellular carcinomatransarterial chemoembolizationdrug-eluting beadlenvatinibpd-1 inhibitorcombined therapy |
| spellingShingle | Wu SJ Ruan DD Wu QY Tang Y Zhang JH Cai SL Zhou YF Luo JW Fang ZT Safety and Efficacy of Drug-Eluting Bead Transarterial Chemoembolization Combined with Lenvatinib and Anti-PD-1 Antibodies for Unresectable Hepatocellular Carcinoma: A Retrospective Analysis Journal of Hepatocellular Carcinoma unresectable hepatocellular carcinoma transarterial chemoembolization drug-eluting bead lenvatinib pd-1 inhibitor combined therapy |
| title | Safety and Efficacy of Drug-Eluting Bead Transarterial Chemoembolization Combined with Lenvatinib and Anti-PD-1 Antibodies for Unresectable Hepatocellular Carcinoma: A Retrospective Analysis |
| title_full | Safety and Efficacy of Drug-Eluting Bead Transarterial Chemoembolization Combined with Lenvatinib and Anti-PD-1 Antibodies for Unresectable Hepatocellular Carcinoma: A Retrospective Analysis |
| title_fullStr | Safety and Efficacy of Drug-Eluting Bead Transarterial Chemoembolization Combined with Lenvatinib and Anti-PD-1 Antibodies for Unresectable Hepatocellular Carcinoma: A Retrospective Analysis |
| title_full_unstemmed | Safety and Efficacy of Drug-Eluting Bead Transarterial Chemoembolization Combined with Lenvatinib and Anti-PD-1 Antibodies for Unresectable Hepatocellular Carcinoma: A Retrospective Analysis |
| title_short | Safety and Efficacy of Drug-Eluting Bead Transarterial Chemoembolization Combined with Lenvatinib and Anti-PD-1 Antibodies for Unresectable Hepatocellular Carcinoma: A Retrospective Analysis |
| title_sort | safety and efficacy of drug eluting bead transarterial chemoembolization combined with lenvatinib and anti pd 1 antibodies for unresectable hepatocellular carcinoma a retrospective analysis |
| topic | unresectable hepatocellular carcinoma transarterial chemoembolization drug-eluting bead lenvatinib pd-1 inhibitor combined therapy |
| url | https://www.dovepress.com/safety-and-efficacy-of-drug-eluting-bead-transarterial-chemoembolizati-peer-reviewed-fulltext-article-JHC |
| work_keys_str_mv | AT wusj safetyandefficacyofdrugelutingbeadtransarterialchemoembolizationcombinedwithlenvatinibandantipd1antibodiesforunresectablehepatocellularcarcinomaaretrospectiveanalysis AT ruandd safetyandefficacyofdrugelutingbeadtransarterialchemoembolizationcombinedwithlenvatinibandantipd1antibodiesforunresectablehepatocellularcarcinomaaretrospectiveanalysis AT wuqy safetyandefficacyofdrugelutingbeadtransarterialchemoembolizationcombinedwithlenvatinibandantipd1antibodiesforunresectablehepatocellularcarcinomaaretrospectiveanalysis AT tangy safetyandefficacyofdrugelutingbeadtransarterialchemoembolizationcombinedwithlenvatinibandantipd1antibodiesforunresectablehepatocellularcarcinomaaretrospectiveanalysis AT zhangjh safetyandefficacyofdrugelutingbeadtransarterialchemoembolizationcombinedwithlenvatinibandantipd1antibodiesforunresectablehepatocellularcarcinomaaretrospectiveanalysis AT caisl safetyandefficacyofdrugelutingbeadtransarterialchemoembolizationcombinedwithlenvatinibandantipd1antibodiesforunresectablehepatocellularcarcinomaaretrospectiveanalysis AT zhouyf safetyandefficacyofdrugelutingbeadtransarterialchemoembolizationcombinedwithlenvatinibandantipd1antibodiesforunresectablehepatocellularcarcinomaaretrospectiveanalysis AT luojw safetyandefficacyofdrugelutingbeadtransarterialchemoembolizationcombinedwithlenvatinibandantipd1antibodiesforunresectablehepatocellularcarcinomaaretrospectiveanalysis AT fangzt safetyandefficacyofdrugelutingbeadtransarterialchemoembolizationcombinedwithlenvatinibandantipd1antibodiesforunresectablehepatocellularcarcinomaaretrospectiveanalysis |